Low-Density Lipoprotein and High-Density Lipoprotein Particle Subclasses Predict Coronary Events and Are Favorably Changed by Gemfibrozil Therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial | Zendy

James D. Otvos | Zendy; Dorothea Collins | Zendy; David S. Freedman | Zendy; Irina Shalaurova | Zendy; Ernst J. Schaefer | Zendy; Judith McNamara | Zendy; Hanna E. Bloomfield | Zendy; Sander J. Robins | Zendy

Open Access

Low-Density Lipoprotein and High-Density Lipoprotein Particle Subclasses Predict Coronary Events and Are Favorably Changed by Gemfibrozil Therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial

Author(s) -

James D. Otvos,

Dorothea Collins,

David S. Freedman,

Irina Shalaurova,

Ernst J. Schaefer,

Judith McNamara,

Hanna E. Bloomfield,

Sander J. Robins

Publication year - 2006

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.105.565135

Subject(s) - gemfibrozil , medicine , lipoprotein particle , lipoprotein , high density lipoprotein , veterans affairs , low density lipoprotein , cardiology , cholesterol , very low density lipoprotein

Changes in conventional lipid risk factors with gemfibrozil treatment only partially explain the reductions in coronary heart disease (CHD) events experienced by men in the Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT). We examined whether measurement of low-density lipoprotein (LDL) and high-density lipoprotein (HDL) particle subclasses provides additional information relative to CHD risk reduction.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research